ArticleJPGN reports2026
Frequency and impact of repeat colonoscopy as a treat-to-target approach in pediatric inflammatory bowel disease.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Endoscopic healing (EH) is a treatment target in inflammatory bowel disease (IBD). However, adherence to repeat colonoscopy (RC) for EH assessment in pediatrics remains variable. We aimed to evaluate the frequency and timing of RC after diagnosis and its impact on treatment decisions at a large pediatric IBD center. Methods: We conducted a retrospective cohort study of pediatric patients diagnosed with IBD January 2019 to December 2021 using an internal patient database and electronic medical records. Data included demographics, treatments, timing of RC, reasons for no RC (if not completed), and therapy modifications following RC (medication escalations and de-escalations). The study took place within the context of an institutional quality improvement project aimed at improving RC rates within 15 months of diagnosis. Results: Of 325 patients diagnosed via baseline colonoscopy during the study interval, 91% underwent RC; 8% within 6 months due to inadequate primary therapy response, 67% between 7 and 15 months, and 16% beyond 15 months. Among the 272 patients with a RC > 6 months postdiagnosis, therapy modification occurred in 39% (107/272), with 81% (87/107) requiring medication escalation, 16% (17/107) medication de-escalation, and 3% (3/107) surgical intervention. Only 3% of patients declined a RC due to patient/family preference. Conclusions: Adherence to the treat-to-target strategy recommending RC within 15 months of diagnosis was high, exceeding previously reported pediatric rates. Only 3% of patients/families declined RC despite this being a perceived barrier toward assessment of EH. Therapy adjustments post-RC were frequent, underscoring the importance of mucosal assessment in guiding treatment optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.